ES2594704T3 - Compuestos con actividad anticancerosa - Google Patents

Compuestos con actividad anticancerosa Download PDF

Info

Publication number
ES2594704T3
ES2594704T3 ES08829410.3T ES08829410T ES2594704T3 ES 2594704 T3 ES2594704 T3 ES 2594704T3 ES 08829410 T ES08829410 T ES 08829410T ES 2594704 T3 ES2594704 T3 ES 2594704T3
Authority
ES
Spain
Prior art keywords
death
cells
cdcl3
optionally substituted
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08829410.3T
Other languages
English (en)
Spanish (es)
Inventor
Takumi Kawabe
Machiyo Ishigaki
Takuji Sato
Sayaka Yamamoto
Yoko Hasegawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Canbas Co Ltd
Original Assignee
Canbas Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Canbas Co Ltd filed Critical Canbas Co Ltd
Application granted granted Critical
Publication of ES2594704T3 publication Critical patent/ES2594704T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • C07D207/448—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
    • C07D207/452—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide with hydrocarbon radicals, substituted by hetero atoms, directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/50—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ES08829410.3T 2007-04-11 2008-04-11 Compuestos con actividad anticancerosa Active ES2594704T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91125807P 2007-04-11 2007-04-11
US911258P 2007-04-11
PCT/IB2008/003036 WO2009031040A2 (en) 2007-04-11 2008-04-11 Compounds with anti-cancer activity

Publications (1)

Publication Number Publication Date
ES2594704T3 true ES2594704T3 (es) 2016-12-22

Family

ID=39939984

Family Applications (3)

Application Number Title Priority Date Filing Date
ES08829410.3T Active ES2594704T3 (es) 2007-04-11 2008-04-11 Compuestos con actividad anticancerosa
ES16165912T Active ES2732230T3 (es) 2007-04-11 2008-04-11 Compuestos que anulan el punto de control G2 del ciclo celular para una utilización en el tratamiento del cáncer
ES19167943T Active ES2927954T3 (es) 2007-04-11 2008-04-11 Compuestos 2,5-dioxo-azolina N-sustituidos para la utilización en el tratamiento del cáncer

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES16165912T Active ES2732230T3 (es) 2007-04-11 2008-04-11 Compuestos que anulan el punto de control G2 del ciclo celular para una utilización en el tratamiento del cáncer
ES19167943T Active ES2927954T3 (es) 2007-04-11 2008-04-11 Compuestos 2,5-dioxo-azolina N-sustituidos para la utilización en el tratamiento del cáncer

Country Status (17)

Country Link
US (2) US8084454B2 (OSRAM)
EP (4) EP3088397B1 (OSRAM)
JP (2) JP5635396B2 (OSRAM)
KR (1) KR101475311B1 (OSRAM)
CN (2) CN101720323A (OSRAM)
AU (1) AU2008294410B2 (OSRAM)
BR (2) BRPI0810911B1 (OSRAM)
CA (4) CA3188320A1 (OSRAM)
DK (2) DK3567035T3 (OSRAM)
ES (3) ES2594704T3 (OSRAM)
HU (2) HUE059861T2 (OSRAM)
IL (4) IL289165B2 (OSRAM)
MX (3) MX391154B (OSRAM)
NZ (1) NZ580237A (OSRAM)
RU (1) RU2482111C2 (OSRAM)
WO (1) WO2009031040A2 (OSRAM)
ZA (1) ZA200906960B (OSRAM)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008294410B2 (en) * 2007-04-11 2012-09-06 Canbas Co., Ltd. Compounds with anti-cancer activity
US8227202B2 (en) 2008-07-10 2012-07-24 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
EP3620154A1 (en) * 2009-02-06 2020-03-11 University Of Southern California Therapeutic compositions comprising monoterpenes
US20100215644A1 (en) * 2009-02-25 2010-08-26 Nodality, Inc. A Delaware Corporation Analysis of nodes in cellular pathways
EP3769754A1 (en) 2010-03-03 2021-01-27 Neonc Technologies, Inc. Pharmaceutical compositions comprising monoterpenes
US20160038600A1 (en) 2012-08-03 2016-02-11 Neonc Technologies Inc. Pharmaceutical compositions comprising poh derivatives
EP2883543B1 (en) 2010-08-27 2016-11-16 Neonc Technologies Inc. Pharmaceutical compositions comprising perillyl alcohol carbamates
EP4656641A2 (en) 2010-12-17 2025-12-03 University of Southern California Methods and devices for using isoperillyl alcohol
WO2013020024A2 (en) * 2011-08-03 2013-02-07 Karyopharm Therapeutics, Inc. Maleimide compounds and methods of treatment
WO2013169600A1 (en) * 2012-05-09 2013-11-14 Delmar Pharmaceuticals Veterinary use of dianhydrogalactitol, diacetyldianhydrogalactitol, and dibromodulcitol to treat malignancies
IN2014MN02512A (OSRAM) 2012-06-14 2015-07-17 Daiichi Sankyo Co Ltd
EP2951174B1 (en) * 2013-01-30 2017-04-26 Bayer Pharma Aktiengesellschaft Amino-substituted isothiazoles
US9540462B2 (en) 2014-12-05 2017-01-10 Massachusetts Institute Of Technology Catechol-rich polymers from N-substituted maleimides
EP3250550B1 (en) 2015-01-26 2023-04-05 Ottawa Hospital Research Institute Compositions and methods for viral sensitization
AU2016219257B2 (en) 2015-02-12 2020-06-25 University Of Southern California Pharmaceutical compositions comprising perillyl alcohol derivatives
EP3429997A1 (de) 2016-03-16 2019-01-23 Bayer CropScience Aktiengesellschaft N-(cyanbenzyl)-6-(cyclopropylcarbonylamino)-4-(phenyl)-pyridin-2-carboxamid-derivate und verwandte verbindungen als pestizide pflanzenschutzmittel
USD915100S1 (en) 2016-03-31 2021-04-06 Ocean 22, Llc Spooled item holding device
USD801721S1 (en) 2016-03-31 2017-11-07 Patricia Grayson Briden Spooled item holding device
TW201811766A (zh) 2016-08-29 2018-04-01 瑞士商諾華公司 N-(吡啶-2-基)吡啶-磺醯胺衍生物及其用於疾病治療之用途
WO2019148181A1 (en) 2018-01-29 2019-08-01 Cognos Therapeutics, Inc. Intratumoral delivery of bortezomib
JP7015396B2 (ja) 2018-02-02 2022-02-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グレリンｏ－アシルトランスフェラーゼ（ｇｏａｔ）阻害剤としての、ベンジル－、（ピリジン－３－イル）メチル－または（ピリジン－４－イル）メチル置換オキサジアゾロピリジン誘導体
JOP20200187A1 (ar) 2018-02-02 2020-07-29 Boehringer Ingelheim Int مشتقات ترايازولو بيريميدين للاستخدام كمثبطات جريلين o- أسيل ترانسفيراز (goat)
CN111936125B (zh) 2018-02-08 2025-03-04 南加州大学 穿透血脑屏障的方法
JP7702968B2 (ja) 2020-05-22 2025-07-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アルキル７－アミノ－５－メチル－［１，２，５］オキサジアゾロ［３，４－ｂ］ピリジンカルボキシレートの製造方法
ES2991340T3 (es) 2020-05-22 2024-12-03 Boehringer Ingelheim Int Procedimiento continuo de fabricación de 7-amino-5-metil-[1,2,5]oxadiazolo[3,4-b]piridín-carboxilato de alquilo
EP4415700A4 (en) * 2021-10-15 2025-12-24 Univ Missouri P1B TYPE ATPASES INHIBITORS
CN114425054A (zh) * 2022-01-20 2022-05-03 中国人民解放军军事科学院军事医学研究院 一种蛋白酶体抑制剂Bortezomib在抗辐射损伤中的用途
CN120247782B (zh) * 2025-06-04 2025-08-19 北京颖泰嘉和生物科技股份有限公司 氟吡菌酰胺类化合物及其制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5564557A (en) * 1978-11-08 1980-05-15 Mitsui Toatsu Chem Inc Diphenyl ether compound and herbicide containing the same
IL81307A0 (en) * 1986-01-23 1987-08-31 Union Carbide Agricult Method for reducing moisture loss from plants and increasing crop yield utilizing nitrogen containing heterocyclic compounds and some novel polysubstituted pyridine derivatives
US5635966A (en) * 1994-01-11 1997-06-03 Hewlett-Packard Company Edge feed ink delivery thermal inkjet printhead structure and method of fabrication
JPH07224032A (ja) * 1994-02-09 1995-08-22 Mitsui Petrochem Ind Ltd Ｎ−アリールオキシフタルイミド誘導体、その製造方 法及びそれを有効成分として含有する除草剤
JPH07244032A (ja) * 1994-03-01 1995-09-19 Ishikawajima Harima Heavy Ind Co Ltd 溶接部検査装置
WO1997009325A1 (en) * 1995-09-01 1997-03-13 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
US5935966A (en) * 1995-09-01 1999-08-10 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
CA2245029A1 (en) * 1998-03-13 1999-09-13 University Of British Columbia Granulatimide compounds as g2 checkpoint inhibitors
US6205557B1 (en) 1998-06-09 2001-03-20 At&T Corp. Redundant call processing
JP2002530299A (ja) * 1998-11-24 2002-09-17 ビーエーエスエフ アクチェンゲゼルシャフト ピロリドン類を活性化合物として含有する殺真菌剤
US6881575B1 (en) 1999-09-22 2005-04-19 Canbas Co., Ltd. Compositions and methods for inhibiting G2 cell cycle arrest and sensitizing cells to DNA damaging agents
DE50104105D1 (de) * 2000-02-26 2004-11-18 Basf Ag Fungizide mittel enthaltend als wirkstoffe pyrrolidone und deren verwendung bei der behandlung von pflanzen
JP2002318434A (ja) * 2001-04-23 2002-10-31 Konica Corp ハロゲン化銀写真感光材料、処理方法、および画像形成方法
FR2826653B1 (fr) * 2001-06-29 2005-10-14 Servier Lab Nouveaux derives de pyrido-pyrido-pyrrolo[3,2-g]pyrrolo [3,4-e]-indole et pyrido-pyrrolo[2,3-a]pyrrolo[3,4-c] carbazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN100577631C (zh) * 2002-06-06 2010-01-06 坎巴斯有限公司 消除dna损伤导致的细胞周期g2关卡和/或增强dna损伤性治疗抗癌活性的化合物
WO2005024755A2 (en) * 2002-12-31 2005-03-17 Deciphera Pharmaceuticals, Llc. Medicaments for the treatment of neurodegenerative disorders or diabetes
WO2005011573A2 (en) * 2003-08-01 2005-02-10 Auspex Pharmaceuticals, Inc. Novel therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders
US7932281B2 (en) * 2004-03-10 2011-04-26 Kureha Corporation Amine-based compound and use thereof
WO2005097765A1 (en) * 2004-03-31 2005-10-20 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
CN101115724A (zh) * 2005-02-08 2008-01-30 默克公司 关卡激酶抑制剂
EP1931657B1 (en) * 2005-08-17 2013-12-25 Merck Sharp & Dohme Corp. Novel high affinity quinoline-based kinase ligands
EP1960386A2 (en) * 2005-11-01 2008-08-27 Janssen Pharmaceutica N.V. Substituted cycloalkylpyrrolones as allosteric modulators of glucokinase
EP2005957B1 (en) * 2006-03-31 2012-05-30 Takeda Pharmaceutical Company Limited Acid secretion inhibitor
US20080221103A1 (en) * 2007-03-09 2008-09-11 Orchid Research Laboratories Ltd. New heterocyclic compounds
AU2008294410B2 (en) * 2007-04-11 2012-09-06 Canbas Co., Ltd. Compounds with anti-cancer activity

Also Published As

Publication number Publication date
ZA200906960B (en) 2010-12-29
HUE029370T2 (hu) 2017-02-28
EP3567035A1 (en) 2019-11-13
EP3567035B1 (en) 2022-06-01
HK1139143A1 (zh) 2010-09-10
EP2152692B9 (en) 2020-03-25
JP5635396B2 (ja) 2014-12-03
NZ580237A (en) 2012-06-29
EP4074704A1 (en) 2022-10-19
BRPI0810911A2 (pt) 2021-03-30
US20110092514A1 (en) 2011-04-21
CA3030510A1 (en) 2009-03-12
JP2010523644A (ja) 2010-07-15
MX374896B (es) 2025-03-04
CA2684037A1 (en) 2009-03-12
EP3088397A1 (en) 2016-11-02
KR101475311B1 (ko) 2014-12-23
IL289165A (en) 2022-02-01
US8415357B2 (en) 2013-04-09
BRPI0810911B1 (pt) 2022-05-17
DK2152692T3 (en) 2016-09-26
CA2913840C (en) 2019-03-05
EP2152692B1 (en) 2016-06-15
RU2482111C2 (ru) 2013-05-20
EP3088397B1 (en) 2019-04-10
IL309201A (en) 2024-02-01
CN105175394B (zh) 2018-06-08
US8084454B2 (en) 2011-12-27
DK3567035T3 (da) 2022-09-05
CN105175394A (zh) 2015-12-23
CN101720323A (zh) 2010-06-02
IL289165B2 (en) 2024-05-01
JP2014012706A (ja) 2014-01-23
IL242883B (en) 2022-01-01
RU2009141619A (ru) 2011-05-20
CA2684037C (en) 2016-02-16
ES2732230T3 (es) 2019-12-12
HUE059861T2 (hu) 2023-01-28
WO2009031040A3 (en) 2009-05-14
AU2008294410A1 (en) 2009-03-12
IL201380A0 (en) 2010-05-31
WO2009031040A2 (en) 2009-03-12
AU2008294410B2 (en) 2012-09-06
CA3030510C (en) 2023-03-14
IL289165B1 (en) 2024-01-01
EP2152692A2 (en) 2010-02-17
BR122022005149B1 (pt) 2022-09-27
MX2020009403A (es) 2022-03-31
MX391154B (es) 2025-03-21
CA3188320A1 (en) 2009-03-12
US20080275057A1 (en) 2008-11-06
KR20090128560A (ko) 2009-12-15
MX2009011025A (es) 2010-01-25
CA2913840A1 (en) 2009-03-12
ES2927954T3 (es) 2022-11-14

Similar Documents

Publication Publication Date Title
ES2594704T3 (es) Compuestos con actividad anticancerosa
JP6861858B2 (ja) Ｓｓａｏ阻害剤
Park et al. New imidazo [2, 1-b] thiazole derivatives: Synthesis, in vitro anticancer evaluation, and in silico studies
AU2018269348B2 (en) Histone deacetylases (HDACs) inhibitors
Basu et al. Structure-based design and synthesis of covalent-reversible inhibitors to overcome drug resistance in EGFR
EP1917262A1 (en) Piperidine and piperazine derivatives as p2x3 antagonists
Jin et al. SAR and molecular mechanism study of novel acylhydrazone compounds targeting HIV-1 CA
WO2004016606A1 (en) Pyrazole inhibitors of the transforming growth factor
CN106588885A (zh) 2‑取代芳环‑嘧啶类衍生物及制备和应用
Zhang et al. Design, synthesis and anticancer activities of diaryl urea derivatives bearing N-acylhydrazone moiety
AU2012229859B2 (en) Nitrogen-containing saturated heterocyclic compound
CN113968824A (zh) 一种2,3,5-三取代吡嗪类化合物及其制备方法和应用
CN106831605A (zh) 一种取代二芳基嘧啶类衍生物及其制备方法与应用
CN107721919B (zh) 苯基喹啉类trpv1拮抗剂及其制备方法和应用
DE60019117T2 (de) Substituierte benzamide als inhibitoren von rhinovirus 3c protease
KR101827660B1 (ko) 플루오로페닐 피라졸 화합물
US4341893A (en) Quinazoline derivatives
Yang et al. Synthesis and quantitative structure–activity relationships study for phenylpropenamide derivatives as inhibitors of hepatitis B virus replication
JP6228667B2 (ja) 新規な抗真菌性オキソジヒドロピリジンカルボヒドラジド誘導体
BR112020021664A2 (pt) composto de formamida, método de preparação do mesmo e aplicação do mesmo
EP4382100A1 (en) N-acylhydrazone compounds capable of inhibiting nav1.7 and/or nav1.8, processes for the preparation thereof, compositions, uses, methods for treatment using same, and kits
CN103012381B (zh) 苯基呋喃类化合物、其制备方法及在制备抗心律失常药物中的应用
CN105968095B (zh) 吲哚芳砜类衍生物及其制备方法与应用
KR102253652B1 (ko) 신규한 암전이 억제 활성을 갖는 화합물, 이의 제조방법 및 상기 화합물을 포함하는 암 전이 및 침윤 억제, 또는 암 치료용 약학적 조성물
CA2800836A1 (en) Riminophenazines with 2-(heteroaryl)amino substituents and their anti-microbial activity